Evaluation of Perioperative Management of Curative Anticoagulants in the Geriatric Perioperative Unit in Patient Hospitalized for Femoral Neck Fracture.

Completed

• Conditions: Femoral Neck Fractures; Anticoagulants; Circulating, Hemorrhagic Disorder

• Registration Number: NCT05286671
• Lead Sponsor: Centre Hospitalier Universitaire de Nīmes

Brief Summary

Pilot study to evaluate the management of curative anticoagulant prescriptions pre- and postoperatively in elderly patients hospitalized for femoral neck fracture.

Detailed Description

Not available

Study Timeline

• Study Start: 2022-02-01
• Study First Submitted: 2022-02-18
• Status Verified: 2022-03
• Primary Completion: 2022-03-11
• Study Completion: 2022-03-11
• Study First Submitted QC: 2022-03-17
• Study First Posted: 2022-03-18
• Last Update Submitted: 2022-04-19
• Last Update Posted: 2022-04-26

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

• Patient 75 years or older
• Hospitalized in the geriatric perioperative unit for a femoral neck fracture between 18/11/2019 and 30/06/2021
• Treated with a curative anticoagulant at entry
• Patient enrolled in or receiving a social security plan

Exclusion Criteria

• Orthopedic patient housed in the geriatric perioperative unit
• Patient who objected to the use of their data

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Rate of compliance with the recommendations for vitamin K antagonists (VKA).	Day 0	Rate of compliance with the french health authority (HAS) recommendations for VKA
Rate of compliance with the recommendations for direct oral anticoagulants (DOAC)..	Day 0	Rate of compliance with the french working group on perioperative haemostasis (GIHP) recommendations for DOACrecommendations for DOA.

Secondary Outcome Measures

Name	Time	Method
Description of the evolution of the plasma dosage of DOAC and the international normalized ratio (INR) and analysis of the operative delay	Day 0	Value of preoperative DOAC plasma dosage, value of INR dosage pre- and post-op, analysis of the operative delay
Evaluation of the morbi-mortality	Day 0	Mortality, re-hospitalizations at 30 days, characterization of bleeding complications, characterization of thrombotic complications
Number of pharmaceutical interventions	Day 0	Number of pharmaceutical interventions regarding anticoagulant prescriptions
description of the population	Day 0	age, weight, height, body mass index, comorbidities
description of pharmaceutical interventions	Day 0	description of pharmaceutical interventions

Trial Locations

Locations (1)

Chu Nimes; 🇫🇷 Nimes, France